Lonza Group AG (0QNO)
London Exchange · UK · prices in CHF · close of 19 Oct 2026
Key indicators
| Last close | CHF 611.80 |
|---|---|
| 52-week range | 452.76 – 613.00 |
| Return, 1 month / 3 months | +12.1% / +14.1% |
| Return, 1 year / 3 years | +12.1% / +48.0% |
| Trend | Uptrend |
| RSI (14) | 66 |
| Volatility (1 year) | 23.9% |
| Worst drawdown (1 year) | -20.2% |
| Average daily value traded | 32.14M CHF |
| Dividend yield | 0.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Lonza Group is a Swiss contract development and manufacturing company that serves pharmaceutical, biotech and specialty ingredient customers. It makes active pharmaceutical ingredients, biologics and cell and gene therapy products for drug developers, and supplies microbial control and hygiene ingredients for consumer and industrial markets. The company is based in Basel, Switzerland, and works with healthcare and life-science customers around the world through its manufacturing and development services.
Lonza Group AG trades under the code 0QNO on the London Exchange in UK, with its price quoted in Swiss francs (CHF). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Lonza Group AG (0QNO) trades on the London Exchange in UK. It last closed at CHF 611.80 on 19 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 330 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 12.1% and over the last three months it rose 14.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 84 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 14.7% | ||
| From 52-week high | 0.0% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 14.1% | ||
| 6-month return | 19.9% | ||
| 12-month return, skipping the last month | 0.0% | ||
| Stability (higher is calmer) | 75 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 23.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.2% | ||
| Liquidity | 82 · Strong | Trades actively. | |
| Average daily value traded | 32.14M CHF | ||
| Zero-volume days | 0.0% | ||
| Income | 40 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +6.5% |
|---|---|
| 1 month | +12.1% |
| 3 months | +14.1% |
| 6 months | +19.9% |
| 1 year | +12.1% |
| 3 years | +48.0% |
| 5 years | – |
Signals
| 50-day / 200-day average | 570.76 / 533.26 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 13.47 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 12 May 2026 | CHF 2.5000 |
| 13 May 2025 | CHF 2.0000 |
| 13 May 2024 | CHF 2.0000 |
| 9 May 2023 | CHF 1.7500 |
| 9 May 2022 | CHF 1.5000 |
| 10 May 2021 | CHF 1.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.